Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Retained Earnings: 2010-2024

Historic Retained Earnings for Vanda Pharmaceuticals (VNDA) over the last 15 years, with Dec 2024 value amounting to -$174.3 million.

  • Vanda Pharmaceuticals' Retained Earnings fell 49.71% to -$253.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$253.6 million, marking a year-over-year decrease of 49.71%. This contributed to the annual value of -$174.3 million for FY2024, which is 12.16% down from last year.
  • Vanda Pharmaceuticals' Retained Earnings amounted to -$174.3 million in FY2024, which was down 12.16% from -$155.4 million recorded in FY2023.
  • Over the past 5 years, Vanda Pharmaceuticals' Retained Earnings peaked at -$155.4 million during FY2023, and registered a low of -$197.3 million during FY2020.
  • In the last 3 years, Vanda Pharmaceuticals' Retained Earnings had a median value of -$157.9 million in 2022 and averaged -$162.5 million.
  • Per our database at Business Quant, Vanda Pharmaceuticals' Retained Earnings grew by 16.80% in 2021 and then fell by 12.16% in 2024.
  • Yearly analysis of 5 years shows Vanda Pharmaceuticals' Retained Earnings stood at -$197.3 million in 2020, then grew by 16.80% to -$164.2 million in 2021, then rose by 3.82% to -$157.9 million in 2022, then grew by 1.59% to -$155.4 million in 2023, then fell by 12.16% to -$174.3 million in 2024.